Amicus Therapeutics Valuation
| FOLD Stock | USD 14.30 0.01 0.07% |
At this time, the firm appears to be fairly valued. Amicus Therapeutics shows a prevailing Real Value of $13.81 per share. The current price of the firm is $14.3. Our model approximates the value of Amicus Therapeutics from analyzing the firm fundamentals such as Current Valuation of 4.67 B, profit margin of (0.02) %, and Return On Equity of -0.0687 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Amicus Therapeutics' valuation include:
Price Book 19.4819 | Enterprise Value | Enterprise Value Ebitda 78.753 | Price Sales 7.498 | Forward PE 17.6056 |
Fairly Valued
Today
Please note that Amicus Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Amicus Therapeutics is based on 3 months time horizon. Increasing Amicus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Amicus stock is determined by what a typical buyer is willing to pay for full or partial control of Amicus Therapeutics. Since Amicus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amicus Stock. However, Amicus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.3 | Real 13.81 | Target 14.5 | Hype 14.31 |
The real value of Amicus Stock, also known as its intrinsic value, is the underlying worth of Amicus Therapeutics Company, which is reflected in its stock price. It is based on Amicus Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Amicus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Amicus Therapeutics helps investors to forecast how Amicus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amicus Therapeutics more accurately as focusing exclusively on Amicus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Amicus Therapeutics' intrinsic value based on its ongoing forecasts of Amicus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Amicus Therapeutics' closest peers. If more than one evaluation category is relevant for Amicus Therapeutics we suggest using both methods to arrive at a better estimate.
Amicus Therapeutics Cash |
|
Amicus Therapeutics Total Value Analysis
Amicus Therapeutics is currently expected to have valuation of 4.67 B with market capitalization of 4.49 B, debt of 443.64 M, and cash on hands of 386.84 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Amicus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.67 B | 4.49 B | 443.64 M | 386.84 M |
Amicus Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.04. Amicus Therapeutics last dividend was issued on the 31st of August 2009. Based on the key indicators related to Amicus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Amicus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Amicus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Amicus Therapeutics has an asset utilization ratio of 67.3 percent. This indicates that the Company is making $0.67 for each dollar of assets. An increasing asset utilization means that Amicus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Amicus Therapeutics Profitability Analysis
Based on Amicus Therapeutics' profitability indicators, Amicus Therapeutics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Amicus Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2004-12-31 | Previous Quarter -24.4 M | Current Value 17.3 M | Quarterly Volatility 32.5 M |
For Amicus Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Amicus Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Amicus Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Amicus Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Amicus Therapeutics over time as well as its relative position and ranking within its peers.
Amicus Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Amicus Therapeutics is estimated to be 0.161675 with future projections ranging from a low of 0.1392 to a high of 0.1975. Amicus Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.04. Please be aware that the consensus of earnings estimates for Amicus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Amicus Therapeutics Earnings Estimation Breakdown
The calculation of Amicus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Amicus Therapeutics is estimated to be 0.161675 with the future projection ranging from a low of 0.1392 to a high of 0.1975. Please be aware that this consensus of annual earnings estimates for Amicus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.14 Lowest | Expected EPS | 0.20 Highest |
Amicus Therapeutics Earnings Projection Consensus
Suppose the current estimates of Amicus Therapeutics' value are higher than the current market price of the Amicus Therapeutics stock. In this case, investors may conclude that Amicus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Amicus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 7 | 65.25% | 0.0 | 0.161675 | -0.04 |
Amicus Therapeutics Ownership Allocation
The majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or is about to change at the company.Amicus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 528.29 M. Net Loss for the year was (56.11 M) with profit before overhead, payroll, taxes, and interest of 537.49 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Amicus Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Amicus Therapeutics and how it compares across the competition.
About Amicus Therapeutics Valuation
The stock valuation mechanism determines Amicus Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Amicus Therapeutics. We calculate exposure to Amicus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Amicus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 546.7 M | 574 M | |
| Pretax Profit Margin | (0.05) | (0.05) | |
| Operating Profit Margin | 0.04 | 0.04 | |
| Net Loss | (0.10) | (0.10) | |
| Gross Profit Margin | 0.81 | 0.85 |
Amicus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Amicus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 304.4 M | |
| Forward Price Earnings | 17.6056 |
Amicus Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Amicus Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Amicus we look at many different elements of the entity such as Amicus's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Amicus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Amicus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Amicus Therapeutics' worth.Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |